

# Predictive factors of venous stenting failure: a systematic review

Ana Carolina Semião <sup>a,b</sup>, Clara Nogueira <sup>a,b</sup>, Andreia Coelho <sup>a,c</sup>, João Peixoto <sup>a,b</sup>, Luís Fernandes <sup>a,b</sup>, Marta Machado <sup>a</sup>, Francisco Basílio <sup>a</sup>, Alexandra Canedo <sup>a</sup>

<sup>a</sup> Angiology and Vascular Surgery Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal; <sup>b</sup> Faculdade de Medicina da Universidade do Porto, Portugal; <sup>c</sup> Angiology and Vascular Surgery Department, Centro Hospitalar do Porto, Portugal

Submitted: September 29, 2021; Reviewed: March 10, 2022; Accepted: October 21, 2022

Presented at: 20th Annual Meeting of the Portuguese Society of Angiology and Vascular Surgery, awarded with prize for Best Oral Communication in Flebology

## ABSTRACT

**OBJECTIVE:** Venous stenting of ilio caval obstructions has become a more frequent procedure over the last two decades. In-stent stenosis and thrombosis are potential complications, causing one of the main causes of symptoms recurrence and impacting quality of life. The aim of this review is to report on the impact of venous stent patency loss, as well on risk factors and management.

**METHODS:** A systematic review was conducted according to the recommendations of the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement.

**RESULTS:** After a literature search, 12 studies (two prospective and 10 retrospective studies) were included in the analysis. A total of 1981 patients (34.1% male) and 2388 limbs (63.6% left side) were assessed. Mean age was 43.5 years (range 16-99).

Indication for stenting included deep venous thrombosis (DVT) (4%), post-thrombotic syndrome (PTS) (18.8%) and non-thrombotic iliac vein lesions (NIVLs) (77.2%). Regarding treatment, most patients were submitted to angioplasty and stenting only (87%). Associated catheter directed thrombolysis or mechanical thrombectomy was performed when indicated (8.4%), and in the remaining an AVF/endophlebectomy was performed (4.6%).

Primary, primary assisted and secondary patency rates at one year ranged from 68-100%, 79-90% and 85.8-100%, respectively. Reported anticoagulation duration after stenting ranged from 1-12 months. In one study involving only patients treated for NIVLs, no anticoagulation was prescribed, and antithrombotic therapy was continued for three months. Follow-up strategies included clinical and imagiological control with a mean follow-up of 19.7 months.

Post-procedural stent re-stenosis was reported in 121 limbs (5.1%) and stent occlusion in 81 limbs (3.4%); the latter was distributed as follows: 11.1% after DVT, 77.8% PTS and 11.1% NIVLs. A total of 186 re-interventions were performed in symptomatic patients.

The prognostic factor most consistently associated with stent failure was thrombotic inflow veins. Other reported factors were incomplete thrombolysis and age younger than 40 years. Stent placement below the inguinal ligament, type of stent and anticoagulation regimen do not seem to affect stent patency.

**CONCLUSION:** Regarding venous lesions of the lower limbs, a selective approach and planning should focus on identification of risk factors for stent failure. It is noteworthy that most stent occlusions occur in post-thrombotic limbs. Stent failure continued after 6 months, emphasizing the importance of an extended surveillance especially on these patients.

**Keywords:** Venous stent thrombosis; postthrombotic syndrome; may-thurner syndrome.



## INTRODUCTION

Venous iliofemoral obstructions can cause debilitating symptoms interfering with daily activities and decreasing patients' quality of life. In the recent past, the most promising treatment consisted of pain medication, compression stockings and anticoagulation.<sup>[1]</sup>

Endovascular recanalization of venous obstructions emerged as a revolutionary procedure with good results having been reported. Initially, treatment was performed with stents developed for the arterial system.<sup>[2]</sup> However, these stents show specific characteristics to overcome the negative effects of atherothrombotic plaques. In the venous system, the main pathophysiologic issue consists of intraluminal vein scarring and is not related to atherothrombotic plaques. Subsequently, dedicated venous stents were developed with favorable features for the venous system, which main goal is to counter extraluminal compression.<sup>[3,4]</sup>

Venous obstructions occur as a result of deep venous thrombosis, post-thrombotic syndrome or non-thrombotic iliac vein lesions, all eligible for endovascular treatment. However, the type of original venous obstruction seems to influence the stent-related outcomes.

The aim of this review is to report on the impact of venous stent patency loss, as well on risk factors and management.

## METHODS

A systematic review was conducted according to the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. The literature search was last updated in April 2021.<sup>[5]</sup>

Search strategy: Using the Medline and Cochrane databases, the following query (((("Endovascular Procedures" [MeSH Terms]) OR ("Endovascular Procedure\*" [Title/Abstract])) OR ("Intravascular Procedure\*" [Title/Abstract])) OR ("Intravascular Technique\*" [Title/Abstract])) OR ("Endovascular Technique\*" [Title/Abstract]) AND (((("May-Thurner Syndrome" [MeSH Terms]) OR ("May-Thurner Syndrome" [Title/Abstract])) OR ("Iliocaval Compression" [Title/Abstract])) OR ("Cockett Syndrome" [Title/Abstract])) OR ("Iliac Vein Compression" [Title/Abstract]) AND (((("Postthrombotic Syndrome" [MeSH Terms]) OR ("Postthrombotic Syndrome" [Title/Abstract])) OR ("Venous Stasis Syndrome" [Title/Abstract])) OR ("PTS" [Title/Abstract]) AND (((((((("Venous Thrombosis" [MeSH Terms]) OR ("Venous Thrombosis" [Title/Abstract])) OR ("Phlebothrombos\*" [Title/Abstract])) OR ("Venous thrombos\*" [Title/Abstract])) OR ("Deep Vein Thrombos\*" [Title/Abstract])) OR ("Deep-Venous Thrombos\*" [Title/Abstract])) OR ("Deep-Vein Thromboses" [Title/Abstract])) OR ("Deep Venous Thrombos\*" [Title/Abstract])) OR ("DVT" [Title/Abstract]) was used for online search.

Eligibility criteria included any publication reporting on iliofemoral venous stenting patency. Exclusion criteria were 1) articles published before 2000, 2) language other than Portuguese or English, 3) studies in paediatric age and cancer, and 4) not human research.

Data extraction and assessment of study quality: Two

reviewers (A.S., C.N.) were responsible for study selection, data extraction, and study quality assessment. Data collected and analyzed included year of publication, type of study (classified as case control, observational retrospective, observational prospective, and randomized control trial [RCT]), type of stent, number of patients in the cohort, rate of stenosis/occlusion, follow up (in months), clinical presentation, identified risk factors, treatment, and outcome.


## RESULTS

Initially a total of 952 potentially relevant articles were selected. After reviewing the records at title or abstract level, 71 articles were read in full and 12 were judged eligible for inclusion, discussing 1981 patients (Figure). These included one prospective single center study, one prospective multicenter study and 10 retrospective single center studies. Studies characteristics, population, stents used, and antiplatelet regimen are available in the Table.

Indication for stenting included DVT (4%), PTS (18.8%) and NIVLs (77.2%). A total of 1807 patients were initially submitted to angioplasty and stenting, and in 174 adjuvant thrombolysis was performed.

A total of 10 studies presented an estimated incidence of stent occlusion, ranging from 0% to 19.9%, affecting 81 patients. A total of 5 studies presented an estimated incidence of in-stent stenosis, ranging from 0% to 32.2%. Follow-up strategies included clinical and imaging control with a mean follow-up of 19.7 months.

**Figure.** Preferred reporting items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram summarizing the literature screening process for studies referring to venous stent patency.



Post-thrombotic femoral leg inflow veins was associated most frequently with stent failure. Other risk factors included incomplete thrombolysis, male gender and age younger than 40 years. Stent placement below the inguinal ligament, type of stent and anticoagulation regimen do not seem to affect stent patency.

Post-procedural stent re-stenosis was reported in 121 limbs (5.1%) and stent occlusion in 81 limbs (3.4%); the latter

was distributed as follows: 11.1% after DVT, 77.8% PTS and 11.1% NIVLs. Considering stent failure treatment, several treatment alternatives were considered. Conservative management was an option in 25 patients (12.4%), who were all clinically asymptomatic. A total of 186 re-interventions were performed in symptomatic patients which included angioplasty, thrombolysis, re-stenting, thrombectomy and arteriovenous fistula construction.

**Table.** Analysis of study characteristics, population, type of stent and antiplatelet regimen

Article (Year)	Study design	Population	Age	Female/male ratio	Sample size	Stent type	Antiplatelet regimen
Knipp 2007 <sup>[6]</sup>	Retrospective; Single centre	NIVL	Median 39 (range 17-71)	6.25	58	not mentioned	Warfarin or Clopidogrel ± Aspirin ("variable period", 6 wk)
Husmann 2007 <sup>[7]</sup>	Retrospective; Single centre	NIVL	Median 34 (16-64)	4.5	11	Wallstent (Boston Scientific)	Initially LMWH and switch to VKA (6 mon)
Srinivas 2015 <sup>[8]</sup>	Prospective; Single center	Acute iliofemoral DVT	Mean 42,1 ± 10,8	1.7	8	Wallstent (Boston Scientific); SMART Stent (Cordis)	Warfarin (12 mo)
Langwieser 2015 <sup>[9]</sup>	Retrospective; Single centre	PTS	Mean 32 ± 11	3.5	9	Nitinol self-expandable stent	Rivaroxaban 20mg + Clopidogrel 75mg (6 mon) then Rivaroxaban 20mg or Aspirin only (after 6 mon)
Vuuren 2017 <sup>[2]</sup>	Retrospective; Single centre	PTS and NIVL	Mean 43,2 ± 14,5 (RANGE 17-81)	1.9	200	Sinus Venous (OptiMed)	not mentioned
Haqq 2017 <sup>[10]</sup>	Retrospective; Single centre	NIVL, acute DVT and PTS	Mean 42,4 ± 18,1	2.0	70		PTS patients received anticoagulation ("long period"), most NIVLs patients received anticoagulation (3 mo), switch to MAPT/DAPT (6 wk)
Jayaraj 2018 <sup>[11]</sup>	Retrospective; Single centre	PTS and NIVL	not mentioned	not mentioned	not mentioned	Wallstent (Boston Scientific); Z-stent (Cook)	DOAC + Aspirin + Cilostazol (≥3 mon)
Menez 2019 <sup>[12]</sup>	Retrospective; Single centre	PTS	Median 41 (17-86)	0.6	95	Cook Zilver (Cook); Sinus XL Flex (OptiMed); Wallstent (Boston Scientific)	Aspirin (75-100mg) + Warfarin or DOAC (1 mo), Warfarin or DOAC (3-6 mo)
Sebastian 2019 <sup>[13]</sup>	Prospective; Multi center	NIVL, acute DVT and PTS	Median 43 (31; 56)	0.9	136	Sinus XL Stent (optimed), Venovo (bard); Sinus Obliquos (optimed), VICI Venous (Boston Scientific); Sinus XL Flex (OptiMed), Zilver Vena Stent (Cook), BlueFlow (admedica); Sinus Superflex stent (optimed), BlueFlow (admedica)	Vitamin K antagonist or DOAC

Article (Year)	Study design	Population	Age	Female/male ratio	Sample size	Stent type	Antiplatelet regimen
Chait 2019 <sup>[11]</sup>	Retrospective; Single centre	NIVL	Median 66 (21-99)	1.9	1061	Wallstent (Boston Scientific)	Clopidogrel 75mg or previous anticoagulation (3 mo)
Avgerinos 2019 <sup>[14]</sup>	Retrospective; Single centre	Acute iliofemoral DVT	Mean 45,8 ± 17,2	1.7	73	Wallstent (Boston Scientific); Protégé stent (ev3 Endovascular Inc.)	VKA/DOAC/LMWH + Aspirin/Clopidogrel (≥3 mo)
Bondarev 2019 <sup>[15]</sup>	Retrospective; Single centre	NIVL	Mean 47 ± 15	13.8	59	Wallstent (Boston Scientific); SMART Stent (Cordis)	not mentioned

**PTS** – Post Thrombotic Syndrome; **NIVL** – non-thrombotic iliac vein lesions; **DVT** – Deep Venous Thrombosis; **LMWH** – Low Molecular Weight Heparin; **VKA** – Vitamin K Antagonists; **DOAC** – Direct Oral Anti-Coagulant; **MAPT** – Mono Anti Platelet Therapy; **DAPT** – Double Anti Platelet Therapy.

Primary, primary assisted and secondary patency rates at one year ranged from 68-100%, 79-90% and 85.8-100%, respectively. Anticoagulation duration after stenting ranged from 1-12 months with no difference between direct oral anticoagulants and vitamin K antagonists, supplemented with antithrombotic therapy.

In one study involving only patients treated for NIVLs, no anticoagulation was prescribed and antiplatelets therapy was continued for three months. The Villalta score was reported in six studies, with a score improvement in all cases.

## DISCUSSION

Venous stent failure is still a poorly understood phenomenon. Endovenous recanalization is a relatively recent treatment alternative for venous outflow obstructions and only in the last few years have venous stents been developed. The most widely accepted definition of venous in-stent stenosis is diameter stenosis ≥50% in the stented vessel segment. Stent occlusion is defined as a complete absence of blood flow in the stented vessel segment.

The most common risk factor for stent failure was the presence of thrombotic inflow veins. The majority of stent occlusions were observed in PTS limbs and this can be explained by the fact that venous inflow in PTS patients is more compromised because of intraluminal scarring below the femoral vein.<sup>[2]</sup>

The different types of stents used did not seem to influence patency rates, even though in the literature patency varies according to different stents. Because dedicated venous stents have been available for only the past few years, there is currently lack for large comparative studies.<sup>[16,17]</sup>

All patients were kept under anticoagulation, with the exception of one study that involved patients treated for NIVLs without venous thrombosis, that were kept exclusively under antiplatelet therapy. In these patients, all stent failures occurred within 6 months. Iliac veins stents placed for venous thrombosis, however, had continued stent failure after 6 months, supporting the role for extended

surveillance in this group of patients.<sup>[10]</sup> Antiplatelet regimens are still not uniform among different studies. Anticoagulation seems preferable to antiplatelet therapy for the first months. Regarding duration of anticoagulation, discontinuing anticoagulation in patients with NIVLs after 6-12 months seems consensual if the stent appears patent on ultrasound. The role of antiplatelet agents following venous stenting appears to be unclear.<sup>[18]</sup> Eijgenraam et al. reported antiplatelet use in venous stenting procedures; although antiplatelets have been shown to be beneficial in preventing restenosis of arterial stents, these effects cannot necessarily be extrapolated to venous stents. One might hypothesize extending antithrombotic treatment for an indefinite period, following venous stenting in PTS patients, especially if multiple DVTs have occurred or if thrombophilia testing is positive.

## CONCLUSION

Stents placed for venous thrombosis are associated with higher disease burdens and intuitively have poorer outcomes compared with stents placed for venous compression. It is noteworthy that most stent occlusions occur in post-thrombotic limbs.

For that reason, a selective approach and planning should focus on identification of risk factors for stent failure. Stent failure continued even after 6 months, emphasizing the importance of an extended surveillance.

**Acknowledgements** None

**Conflicts of interest** None

**Funding** None

## REFERENCES

1. Chait J, Alsheekh A, Aurshina A, Haggerty J, Ostrozhynskyy Y, Rajaei S, et al. Effect of venous access site on postintervention stent thrombosis for nonthrombotic iliac vein stenting. *J Vasc Surg Venous Lymphat Disord* 2020;8:84–8
2. van Vuuren TMAJ, Doganci S, Wittens CHA. Patency rates and clinical outcomes in a cohort of 200 patients treated with a dedicated venous stent. *J Vasc Surg Venous Lymphat Disord* 2018;6:321–9
3. Neglén P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: Long-term stent-related outcome, clinical, and hemodynamic result. *J Vasc Surg* 2007;46:979–90
4. Xue GH, Huang XZ, Ye M, Liang W, Zhang H, Zhang JW, et al. Catheter-directed thrombolysis and stenting in the treatment of iliac vein compression syndrome with acute iliofemoral deep vein thrombosis: Outcome and follow-up. *Ann Vasc Surg* 2014;28:957–63
5. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700
6. Knipp B, Ferguson E, David MW, Narasimham JD, Wojciech Cwikie, Peter KH et al. Factors associated with outcome after interventional treatment of symptomatic iliac vein compression syndrome. *J Vasc Surg* 2007;46:743–9
7. Husmann MJ, Heller G, Kalka C, Savolainen H, Schmidli J, Baumgartner I. Stenting of Common Iliac Vein Obstructions Combined with Regional Thrombolysis and Thrombectomy in Acute Deep Vein Thrombosis. *Eur J Vasc Endovasc Surg* 2007;34, 87–91
8. Srinivas BC, Soumya P, Babu R, Nagesh CM, Naveen A, Manjunath CN. Outcome of venous stenting following catheter directed thrombolysis for acute proximal lower limb venous thrombosis: a prospective study with venous Doppler follow-up at 1-year. *Cardiovasc Interv Ther* 2015;30:320–6
9. Langwieser N, Bernlochner I, Wustrow I, Dirschinger R, Jaitner J, Dommasch M et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction. *Phlebology* 2016;31:430–7
10. Haqq RA, Novak Z, Pearce B, Matthews T, Patterson M, Jordan Jr M, Passman M. Routine extended follow-up surveillance of iliac vein stents for ilio caval venous obstruction may not be warranted. *J Vasc Surg Venous and Lym Dis* 2017;5:500–5
11. Jayaraj A, Buck W, Knight A, Johns B, Raju S, Jackson. Impact of degree of stenosis in May-Thurner syndrome on iliac vein stenting. *J Vasc Surg: Venous and Lym Dis* 2019;7:195–202
12. Menez C, Rodiere M, Ghelfi J, Seinturier C, Martinelli T, Imbert B, et al. Endovascular Treatment of Post-thrombotic Venous Ilio-Femoral Occlusions: Prognostic Value of Venous Lesions Caudal to the Common Femoral Vein. *Cardiovas Intervent Radiol*. 2019;42:1117–27
13. Sebastian T, Spirk D, Engelberger R, Dopheide J, Baumann F, Barco S, et al. Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome. *Thromb Haemost* 2019;119:2064–73
14. Avgerinos E, Saadeddin Z, Abou A, Pandya Y, Hager E, Singh M, et al. Outcomes and predictors of failure of iliac vein stenting after catheter-directed thrombolysis for acute iliofemoral thrombosis. *J Vasc Surg Venous Lymphat Disord* 2019;7:153–161
15. Bondarev S, Eric JK, Timothy H, Victoria AY, Suraj G, Robert LV, et al. Predictors of Disease Recurrence after Venoplasty and Stent Placement for May–Thurner Syndrome. *J Vasc Interv Radiol* 2019;30:1549–54
16. De Wolf MAF, De Graaf R, Kurstjens RLM, Penninx S, Jalaie H, Wittens CHA. Short-Term Clinical Experience with a Dedicated Venous Nitinol Stent: Initial Results with the Sinus-Venous Stent. *Eur J Vasc Endovasc Surg* 2015;50:518–26
17. O’Sullivan G, Sheehan J, Lohan D, Brown JA. Iliofemoral venous stenting. *J Cardiovasc Surg* 2013;54:255–61
18. Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic Therapy Following Venous Stenting: International Delphi Consensus. *Eur J Vasc Endovasc Surg* 2018;55:537–44